Effects of Ethylmethylhydroxypyridine Succinate Therapy in Patients with Cad by EUROASPIREV: Hospital Arm
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to evaluate the efficacy, safety and tolerability of the ethylmethylhydroxypyridine succinate (Mexiprim) in patients after acute coronary syndrome or percutaneous coronary intervention (PCI).
Matherials and methods. 60 patients who were hospitalized in a period of 6 months to 2 years before the evaluation with diagnosis of unstable angina, acute myocardial infarction (AMI), or scheduled percutaneous coronary intervention (PCI) were included in current study. This study was a part of European study EUROASPIRE V – hospital arm, guided by European society of cardiology Euroobservational research programme and was held by European association of cardiovascular prevention and rehabilitation. All patients received basic therapy for CAD according to the recommendations of the ESC and the Ukrainian Society of Cardiology. 30 patients received Mexiprim in a dose of 125 mg 1t. 3 times a day for 2 months. 30 patients made up a control group. To all patients at the beginning of the study and after 6 months echocardiography, ultrasound evaluation of extracranial brachiocephalic arteries, testing on the Hamilton scale of depression and anxiety (HDRS, HARS), the Beck depression scale were performed; all patients completed the questionnaire regarding their basic therapy and compliance.
Results. After the treatment, in the Mexiprim group, compared to the control group, the level of anxiety on the HARS scale was significantly lower (6,0±2,2 inthe Mexiprim group and 7,5±2,5 inthe control group; p<0,05). The percentage of patients with anxiety of different severity in the Mexicrim group decreased from 50% to 30%. When comparing the average score on the Beck depression scale after treatment, significantly lower values were found in the Mexiprim group (8,1±5,8 compared with 12,1±7,0; p=0,04), than in the control group. Similarly, according to Bek’s results, a significant decrease in the number of patients with depression of varying severity (33,3% compared to 62,2%, respectively; p=0,02) was found in the Mexiprim group, but not the control group, after treatment. According to the results of echocardiography, after the treatment, the E/e’ ratio, that reflects keft ventricle filling pressure and the degree of diastolic dysfunction – significantly decreased from 10,3±4,05 to 6,1±3,08 (p=0.001). Moreover, the difference between the groups after treatment in E/e’ ratio was also statistically significant (p<0,0001).
Conclusion. In the Mexiprim group, there were no significant differences in the IMT before and after treatment. In the control group, there was an increase of IMT on both sides, while an increase of IMT in the left common carotid artery was statistically significant. In the group of mexiprim, there was an improvement in the compliance of patients regarding antihypertensive therapy (from 73,3% to 93,3%; p<0,05) and lipid-lowering therapy (from 70% to 90%; p<0,05).##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Коваленко В.М., Долженко М.М., Несукай О.Г., Нудченко О.О., Лурьє С.З. на чолі групи дослідників. Поширеність тривожно-депресивних розладів та їх вплив на серцево-судинні фактори ризику за даними дослідження EUROASPIRE IV – Первинна ланка медичної допомоги // Укр. кард. журнал. – 2015. – С. 11–15. PDF
Jentzer JC, Anavekar NS, Mankad SV, Khasawneh M, White RD, Barsness GW, Rabinstein AA, Kashani KB, Pislaru SV. Echocardiographic left ventricular diastolic dysfunction predicts hospital mortality after out-of-hospital cardiac arrest.// J Crit Care. 2018 Jun 19;47:114–120. https://doi.org/10.1016/j.jcrc.2018.06.016
Kusunose K, Okushi Y et al. Prognostic Value of Frailty and Diastolic Dysfunction in Elderly Patients.// Circ J. 2018 Jul 25;82(8):2103–2110. https://doi.org/10.1253/circj.CJ-18-0017
Johansen ND, Biering-Sorensen T et al. Diastolic dysfunction revisited: A new, feasible, and unambiguous echocardiographic classification predicts major cardiovascular events // Am Heart J. 2017 Jun;188:136–146. https://doi.org/10.1016/j.ahj.2017.03.013
Mogelvang R, Biering-Sørensen T et al. Tissue Doppler echocardiography predicts acute myocardial infarction, heart failure, and cardiovascular death in the general population.// Eur Heart J Cardiovasc Imaging. 2015 Dec;16(12):1331–7. https://doi.org/10.1093/ehjci/jev180
Kim YH, Kim SH et al. Relationship between depression and subclinical left ventricular changes in the general population.// Heart. – 2012. – 98(18): 1378–83. https://doi.org/10.1136/heartjnl-2012-302180
Li Ma, Yanhong Li et al. A New Potential Predictor of Coronary Artery Disease: The Ratio of Mitral Peak Filling Velocity to Mitral Annular Velocity in Early Diastole // Med Sci Monit. – 2017; 23: 1180–1189. https://dx.doi.org/10.12659%2FMSM.901704
Мексидол: применение препарата при остром нарушении мозгового кровообращения. – М.: Фармсофт, 2000. – 13 с.
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI. Ethical Principles for Medical Research Involving Human Subjects. – WMA, 2004 (ХЕЛЬСИНСКАЯ ДЕКЛАРАЦИЯ ВСЕМИРНОЙ МЕДИЦИНСКОЙ АССОЦИАЦИИ. Этические принципы для медицинских исследований с привлечением человека в качестве субъекта). PDF
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging/ J Am Soc Echocardiogr 2016; 29: 277–314. https://doi.org/10.1016/j.echo.2016.01.011
ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology // Eur Heart J. 2013 Oct; 34(38): 2949–3003. https://doi.org/10.1093/eurheartj/eht296
